BMS awarded 2018 ENERGY STAR Partner of the Year Sustained Excellence Award
The company’s environmental efforts honored for the fourth consecutive year.
The US Environmental Protection Agency (EPA) and the US Department of Energy have recognized Bristol-Myers Squibb (BMS) with an ENERGY STAR Partner of the Year Sustained Excellence Award for outstanding efforts to improve the energy efficiency of facilities worldwide. BMS has earned the ENERGY STAR Partner of the Year award for the past 4 consecutive years.
The award confirms BMS’s long-term commitment to environmental responsibility through driving sustainable improvements in energy with a goal of reducing the company use or resources across its drug discovery, development and delivery pipeline.
“We are proud to receive the ENERGY STAR Partner of the Year designation for 4 years, and to increase our recognition with the Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, BMS. “To continue developing innovative medicines for our patients, we have to embrace our responsibility to support our environment, employees and communities. We look forward to our continued partnership with ENERGY STAR to better advance our energy management programs and demonstrate our leadership within the pharmaceutical industry.”
BMS was recognized for the following accomplishments:In addition to the company’s recognition as an ENERGY STAR Partner of the Year, BMS’s R&D site in Hopewell, New Jersey, and the manufacturing site in New Brunswick, New Jersey earned the 2017 Challenge for Industry recognition. The ENERGY STAR Challenge for Industry is a national call-to-action to improve energy efficiency of America’s manufacturers by 10% or more. By taking the ENERGY STAR Challenge, sites set a goal to reduce their energy intensity by 10% within 5 years.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance